schliessen

Filtern

 

Bibliotheken

Determination and modeling of kinetics of cancer cell killing by doxorubicin and doxorubicin encapsulated in targeted liposomes.

Various mathematical approaches have been devised to relate the cytotoxic effect of drugs in cell culture to the drug concentration added to the cell culture medium. Such approaches can satisfactorily account for drug response when the drugs are free in solution, but the approach becomes problematic... Full description

Journal Title: Cancer research January 15, 2004, Vol.64(2), pp.711-718
Main Author: Eliaz, Rom E
Other Authors: Nir, Shlomo , Marty, Cornelia , Szoka, Francis C
Format: Electronic Article Electronic Article
Language: English
Subjects:
ID: ISSN: 0008-5472
Link: http://search.proquest.com/docview/80123713/?pq-origsite=primo
Zum Text:
SendSend as email Add to Book BagAdd to Book Bag
Staff View
recordid: proquest80123713
title: Determination and modeling of kinetics of cancer cell killing by doxorubicin and doxorubicin encapsulated in targeted liposomes.
format: Article
creator:
  • Eliaz, Rom E
  • Nir, Shlomo
  • Marty, Cornelia
  • Szoka, Francis C
subjects:
  • Animals–Administration & Dosage
  • Antibiotics, Antineoplastic–Pharmacokinetics
  • Biological Transport–Toxicity
  • Cell Line, Tumor–Drug Effects
  • Cell Survival–Administration & Dosage
  • Doxorubicin–Pharmacokinetics
  • Drug Carriers–Toxicity
  • Kinetics–Pharmacokinetics
  • Liposomes–Pathology
  • Melanoma, Experimental–Pathology
  • Mice–Pathology
  • Antibiotics, Antineoplastic
  • Drug Carriers
  • Liposomes
  • Doxorubicin
ispartof: Cancer research, January 15, 2004, Vol.64(2), pp.711-718
description: Various mathematical approaches have been devised to relate the cytotoxic effect of drugs in cell culture to the drug concentration added to the cell culture medium. Such approaches can satisfactorily account for drug response when the drugs are free in solution, but the approach becomes problematic when the drug is delivered in a drug delivery system, such as a liposome. To address this problem, we have developed a simple model that assumes that the cytotoxic potency of a drug is a function of the intracellular drug level in a critical compartment. Upon exposure to drug, cell death commences after a lag time, and the cell kill rate is dependent on the amount of drug in the critical intracellular compartment. The computed number of cells in culture, at any time after exposure to the drug, takes into account the cell proliferation rate, the cell kill rate, the average intracellular drug concentration, and a lag time for cell killing. We have applied this model to compare the cytotoxic effect of doxorubicin (DOX), or DOX encapsulated in a liposome that is targeted to CD44 on B16F10 melanoma cells in culture. CD44 is the surface receptor that binds to hyaluronan and is overexpressed on various cancer cells, including B16F10. We have shown previously that the drug encapsulated in hyaluronan-targeted liposomes was more potent than was the free drug. The model required the determination of the cell-associated DOX after the cells were incubated with various concentrations of the free or the encapsulated drug for 3 h, and the quantification of cell number at various times after exposure to the drug. The uptake of encapsulated drug was greater than that of the free drug, and the ratio of cell association of encapsulated:free drug was 1.3 at 0.5 micro g/ml and increased to 3.3 at 20 micro g/ml DOX. The results demonstrate that the enhanced potency of the encapsulated drug could stem from its enhanced uptake. However, in certain cases, where larger amounts of the free drug were added, such that the intracellular amounts of drug exceeded those obtained from the encapsulated drug, the numbers of viable cells were still significantly smaller for the encapsulated drug. This finding demonstrates that for given amounts of intracellular DOX, the encapsulated form was more efficient in killing B16F10 cells than the free drug. The outcome was expressed in the kinetic model as a 5-6-fold larger rate constant of cell killing potency for the encapsulated drug versus the free dru
language: eng
source:
identifier: ISSN: 0008-5472
fulltext: fulltext
issn:
  • 00085472
  • 0008-5472
url: Link


@attributes
ID1190173335
RANK0.07
NO1
SEARCH_ENGINEprimo_central_multiple_fe
SEARCH_ENGINE_TYPEPrimo Central Search Engine
LOCALfalse
PrimoNMBib
record
control
sourcerecordid80123713
sourceidproquest
recordidTN_proquest80123713
sourcesystemOther
pqid80123713
display
typearticle
titleDetermination and modeling of kinetics of cancer cell killing by doxorubicin and doxorubicin encapsulated in targeted liposomes.
creatorEliaz, Rom E ; Nir, Shlomo ; Marty, Cornelia ; Szoka, Francis C
contributorEliaz, Rom E (correspondence author) ; Eliaz, Rom E (record owner)
ispartofCancer research, January 15, 2004, Vol.64(2), pp.711-718
identifierISSN: 0008-5472
subjectAnimals–Administration & Dosage ; Antibiotics, Antineoplastic–Pharmacokinetics ; Biological Transport–Toxicity ; Cell Line, Tumor–Drug Effects ; Cell Survival–Administration & Dosage ; Doxorubicin–Pharmacokinetics ; Drug Carriers–Toxicity ; Kinetics–Pharmacokinetics ; Liposomes–Pathology ; Melanoma, Experimental–Pathology ; Mice–Pathology ; Antibiotics, Antineoplastic ; Drug Carriers ; Liposomes ; Doxorubicin
languageeng
source
descriptionVarious mathematical approaches have been devised to relate the cytotoxic effect of drugs in cell culture to the drug concentration added to the cell culture medium. Such approaches can satisfactorily account for drug response when the drugs are free in solution, but the approach becomes problematic when the drug is delivered in a drug delivery system, such as a liposome. To address this problem, we have developed a simple model that assumes that the cytotoxic potency of a drug is a function of the intracellular drug level in a critical compartment. Upon exposure to drug, cell death commences after a lag time, and the cell kill rate is dependent on the amount of drug in the critical intracellular compartment. The computed number of cells in culture, at any time after exposure to the drug, takes into account the cell proliferation rate, the cell kill rate, the average intracellular drug concentration, and a lag time for cell killing. We have applied this model to compare the cytotoxic effect of doxorubicin (DOX), or DOX encapsulated in a liposome that is targeted to CD44 on B16F10 melanoma cells in culture. CD44 is the surface receptor that binds to hyaluronan and is overexpressed on various cancer cells, including B16F10. We have shown previously that the drug encapsulated in hyaluronan-targeted liposomes was more potent than was the free drug. The model required the determination of the cell-associated DOX after the cells were incubated with various concentrations of the free or the encapsulated drug for 3 h, and the quantification of cell number at various times after exposure to the drug. The uptake of encapsulated drug was greater than that of the free drug, and the ratio of cell association of encapsulated:free drug was 1.3 at 0.5 micro g/ml and increased to 3.3 at 20 micro g/ml DOX. The results demonstrate that the enhanced potency of the encapsulated drug could stem from its enhanced uptake. However, in certain cases, where larger amounts of the free drug were added, such that the intracellular amounts of drug exceeded those obtained from the encapsulated drug, the numbers of viable cells were still significantly smaller for the encapsulated drug. This finding demonstrates that for given amounts of intracellular DOX, the encapsulated form was more efficient in killing B16F10 cells than the free drug. The outcome was expressed in the kinetic model as a 5-6-fold larger rate constant of cell killing potency for the encapsulated drug versus the free drug. The model provides a quantitative framework for comparing the cytotoxic effect in cultured cells when applying the drug in the free form or in a delivery system.
version4
lds50peer_reviewed
links
openurl$$Topenurl_article
openurlfulltext$$Topenurlfull_article
backlink$$Uhttp://search.proquest.com/docview/80123713/?pq-origsite=primo$$EView_record_in_ProQuest_(subscribers_only)
search
creatorcontrib
0Eliaz, Rom E
1Nir, Shlomo
2Marty, Cornelia
3Szoka, Francis C
titleDetermination and modeling of kinetics of cancer cell killing by doxorubicin and doxorubicin encapsulated in targeted liposomes.
subject
0Animals–Administration & Dosage
1Antibiotics, Antineoplastic–Pharmacokinetics
2Biological Transport–Toxicity
3Cell Line, Tumor–Drug Effects
4Cell Survival–Administration & Dosage
5Doxorubicin–Pharmacokinetics
6Drug Carriers–Toxicity
7Kinetics–Pharmacokinetics
8Liposomes–Pathology
9Melanoma, Experimental–Pathology
10Mice–Pathology
11Antibiotics, Antineoplastic
12Drug Carriers
13Liposomes
14Doxorubicin
general
0English
1MEDLINE (ProQuest)
2ProQuest Biological Science Collection
3ProQuest Environmental Science Collection
4ProQuest Natural Science Collection
5ProQuest SciTech Collection
6Agricultural & Environmental Science Database
7Biological Science Database
8Natural Science Collection
9SciTech Premium Collection
10Health Research Premium Collection
11Health Research Premium Collection (Alumni edition)
sourceidproquest
recordidproquest80123713
issn
000085472
10008-5472
rsrctypearticle
creationdate2004
addtitleCancer research
searchscope
01007489
11007527
21007944
310000004
410000006
510000038
610000043
710000050
810000120
910000159
1010000198
1110000200
1210000209
1310000217
1410000234
1510000238
1610000253
1710000260
1810000270
1910000271
2010000302
21proquest
scope
01007489
11007527
21007944
310000004
410000006
510000038
610000043
710000050
810000120
910000159
1010000198
1110000200
1210000209
1310000217
1410000234
1510000238
1610000253
1710000260
1810000270
1910000271
2010000302
21proquest
lsr43
01007489false
11007527false
21007944false
310000004false
410000006false
510000038false
610000043false
710000050false
810000120false
910000159false
1010000198false
1110000200false
1210000209false
1310000217false
1410000234false
1510000238false
1610000253false
1710000260false
1810000270false
1910000271false
2010000302false
contributorEliaz, Rom E
startdate20040115
enddate20040115
citationpf 711 pt 718 vol 64 issue 2
lsr30VSR-Enriched:[pqid, description, doi, eissn]
sort
titleDetermination and modeling of kinetics of cancer cell killing by doxorubicin and doxorubicin encapsulated in targeted liposomes.
authorEliaz, Rom E ; Nir, Shlomo ; Marty, Cornelia ; Szoka, Francis C
creationdate20040115
lso0120040115
facets
frbrgroupid5170286112736998883
frbrtype5
newrecords20181218
languageeng
creationdate2004
topic
0Animals–Administration & Dosage
1Antibiotics, Antineoplastic–Pharmacokinetics
2Biological Transport–Toxicity
3Cell Line, Tumor–Drug Effects
4Cell Survival–Administration & Dosage
5Doxorubicin–Pharmacokinetics
6Drug Carriers–Toxicity
7Kinetics–Pharmacokinetics
8Liposomes–Pathology
9Melanoma, Experimental–Pathology
10Mice–Pathology
11Antibiotics, Antineoplastic
12Drug Carriers
13Liposomes
14Doxorubicin
collection
0MEDLINE (ProQuest)
1ProQuest Biological Science Collection
2ProQuest Environmental Science Collection
3ProQuest Natural Science Collection
4ProQuest SciTech Collection
5Agricultural & Environmental Science Database
6Biological Science Database
7Natural Science Collection
8SciTech Premium Collection
9Health Research Premium Collection
10Health Research Premium Collection (Alumni edition)
prefilterarticles
rsrctypearticles
creatorcontrib
0Eliaz, Rom E
1Nir, Shlomo
2Marty, Cornelia
3Szoka, Francis C
jtitleCancer research
toplevelpeer_reviewed
delivery
delcategoryRemote Search Resource
fulltextfulltext
addata
aulast
0Eliaz
1Nir
2Marty
3Szoka
aufirst
0Rom E
1Shlomo
2Cornelia
3Francis C
au
0Eliaz, Rom E
1Nir, Shlomo
2Marty, Cornelia
3Szoka, Francis C
addauEliaz, Rom E
atitleDetermination and modeling of kinetics of cancer cell killing by doxorubicin and doxorubicin encapsulated in targeted liposomes.
jtitleCancer research
risdate20040115
volume64
issue2
spage711
epage718
pages711-718
issn0008-5472
formatjournal
genrearticle
ristypeJOUR
urlhttp://search.proquest.com/docview/80123713/
doi10.1158/0008-5472.CAN-03-0654
eissn15387445
date2004-01-15